journal
MENU ▼
Read by QxMD icon Read
search

Breast: Official Journal of the European Society of Mastology

journal
https://www.readbyqxmd.com/read/30189381/expression-of-ny-eso-1-mage-a3-prame-and-wt1-in-different-subgroups-of-breast-cancer-an-indication-to-immunotherapy
#1
Anna Tessari, Lorenzo Pilla, Damian Silvia, Matteo Duca, Biagio Paolini, Maria Luisa Carcangiu, Luigi Mariani, Filippo G de Braud, Sara Cresta
OBJECTIVES: Cancer Testis Antigens are immunogenic tumor-specific proteins. We investigated NY-ESO-1, MAGE-A3 and PRAME, in addition to WT1 expression in different Breast Cancer (BC) subtypes. We then evaluated the expression rate of NY-ESO-1 in early Triple Negative breast cancer (TNBC), and investigated whether its expression would be maintained or lost in the metastatic setting to explore possible immunotherapy indication. MATERIALS AND METHODS: Three subgroups of BC patients were selected by the expression of ER, PgR and Her2...
August 29, 2018: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/30216838/frequency-and-characteristics-of-additionally-detected-ipsilateral-breast-lesions-following-recall-at-screening-mammography
#2
Joost Rc Lameijer, Angela Mp Coolen, Joost Nederend, Adri C Voogd, Vivianne Cg Tjan-Heijnen, Lucien Em Duijm
PURPOSE: To determine the frequency and outcome of additionally detected ipsilateral breast abnormalities following recall at screening mammography. METHODS AND MATERIALS: We included a consecutive series of 130,338 screening mammograms obtained between January 1, 2014 and January 1, 2016. During 2-year follow-up, clinical data were collected of all recalls. Women with a bilateral recall (115) and women recalled for multiple lesions in one breast (165) were excluded from the analyses...
August 28, 2018: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/30179779/chemosensitivity-tumor-infiltrating-lymphocytes-tils-and-survival-of-postpartum-pabc-patients-treated-by-neoadjuvant-chemotherapy
#3
Julie Labrosse, Inès Abdennebi, Lucie Thibault, Enora Laas, Hilde Merckelbagh, Charlotte Morel, Thanh Lam, Marick Lae, Fabien Reyal, Anne-Sophie Hamy
BACKGROUND: Pregnancy-associated breast cancer (PABC) refers to breast cancers (BC) diagnosed during pregnancy or shortly after birth. Although the inflammatory environment of post-partum PABC cases (designed as PP-PABC) may be deleterious, so far PP-PABC have scarcely been distinguished from breast cancers diagnosed during pregnancy. Furthermore, whether PP-PABC cases have an enhanced immune infiltration remains unknown. We investigated chemosensitivity, immune infiltration and survival of PP-PABC patients treated by neoadjuvant chemotherapy (NAC) compared to non-PABC matched BC patients...
August 28, 2018: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/30199761/a-systematic-review-of-women-s-knowledge-of-screening-mammography
#4
REVIEW
Kristen Seaman, Peta L Dzidic, Emily Castell, Christobel Saunders, Lauren J Breen
In light of the contention surrounding the benefit-to-harm ratio of screening mammography, this systematic review aimed to understand women's knowledge of screening mammography. The search yielded 35 studies of varying methodologies, published/completed between 1992 and 2017. Data was collected between November 2017 and February 2018 and utilised publications from member countries of the International Cancer Screening Network- Breast Cancer Division. Data was analysed using a narrative synthesis. The results of the review suggest that most women are aware of mammograms, however there was large variability regarding the awareness of false positives/negatives and about the purpose of screening...
August 27, 2018: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/30172804/utility-of-short-interval-follow-up-mammography-after-a-benign-concordant-stereotactic-breast-biopsy-result
#5
Sean Maldonado, Nishant Gandhi, Tony Ha, Patrick Choi, Iraj Khalkhali, Babak N Kalantari, Christine Dauphine
BACKGROUND: There is currently no clear consensus recommendation for the use of short-interval follow-up mammography after a benign-concordant breast biopsy (BCBB), and practice patterns vary widely. The objectives of this study were to evaluate whether a short-interval follow-up mammogram provided clinical utility after stereotactic BCBB and to examine the costs associated with this surveillance strategy. METHODS: A retrospective review of women who underwent a stereotactic breast biopsy yielding benign-concordant results between January 2005 and October 2014 was performed to evaluate findings on subsequent imaging, to calculate compliance with recommended short-interval imaging, and to examine whether subsequent imaging revealed an abnormality at the site of the initial stereotactic BCBB...
August 23, 2018: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/30170202/the-bcy3-bcc-2017-survey-on-physicians-knowledge-attitudes-and-practice-towards-fertility-and-pregnancy-related-issues-in-young-breast-cancer-patients
#6
Matteo Lambertini, Massimo Di Maio, Olivia Pagani, Giuseppe Curigliano, Francesca Poggio, Lucia Del Mastro, Shani Paluch-Shimon, Sibylle Loibl, Ann H Partridge, Isabelle Demeestere, Hatem A Azim, Fedro A Peccatori
BACKGROUND: Fertility and pregnancy-related issues are major concerns for young breast cancer patients. Limited data are available on physicians' knowledge, attitudes and practice in these fields. METHODS: A 26-item questionnaire exploring 3 different topics (fertility preservation, pregnancy after breast cancer and breast cancer during pregnancy) was sent by email to physicians attending the 2016 3rd European School of Oncology (ESO) - European Society for Medical Oncology (ESMO) Breast Cancer in Young Women Conference (BCY3) and the 15th St...
August 22, 2018: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/30153552/therapeutic-drug-monitoring-of-endoxifen-as-an-alternative-for-cyp2d6-genotyping-in-individualizing-tamoxifen-therapy
#7
Aurelia H M de Vries Schultink, Alwin D R Huitema, Jos H Beijnen
Different strategies have been proposed to individualize tamoxifen treatment in order to improve recurrence-free survival in estrogen receptor (ER)-positive breast cancer. To date, the debate remains on which strategy should be used. The objective of this viewpoint is to highlight Therapeutic Drug Monitoring of endoxifen, the active tamoxifen metabolite, as the preferred methodology compared to CYP2D6 genotyping for individualizing tamoxifen therapy for ER-positive breast cancer patients treated in the adjuvant setting...
August 22, 2018: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/30149235/hypofractionation-with-simultaneous-boost-in-breast-cancer-patients-receiving-adjuvant-chemotherapy-a-prospective-evaluation-of-a-case-series-and-review-of-the-literature
#8
Fiorenza De Rose, Antonella Fogliata, Davide Franceschini, Cristina Iftode, Pierina Navarria, Tiziana Comito, Ciro Franzese, Bethania Fernandes, Giovanna Masci, Rosalba Torrisi, Corrado Tinterri, Alberto Testori, Armando Santoro, Marta Scorsetti
INTRODUCTION: To evaluate acute toxicity and cosmetic outcomes of hypofractionated simultaneous integrated boost (SIB) as adjuvant treatment after breast-conserving surgery and adjuvant chemotherapy and to review the association of chemotherapy and short fractionation with boost. MATERIALS AND METHODS: Patients presenting early-stage breast cancer were enrolled in a phase II trial. All patients received VMAT-SIB technique to the whole breast and tumor bed in 15 fractions, for a total dose of 40...
August 22, 2018: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/30176553/influence-of-the-subtype-on-local-recurrence-risk-of-breast-cancer-with-or-without-radiation-therapy
#9
Åsa Wickberg, Anders Magnuson, Lars Holmberg, Hans-Olov Adami, Göran Liljegren
PURPOSE: To investigate if intrinsic subtypes of breast cancer predict different risks of ipsilateral breast tumor recurrence (IBTR) following breast-conserving surgery (BCS) with and without postoperative radiation therapy. PATIENTS AND METHODS: We randomized 381 women with a unifocal T1N0M0 breast cancer to BCS alone (197 women) or BCS plus postoperative radiation therapy (XRT) (184 women). All available histopathological material was re-analyzed with modern immunohistochemical methods (223 women)...
August 21, 2018: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/30138762/reducing-harms-from-treatment-sixteen-years-of-surgery-of-the-axilla-for-screen-detected-breast-cancers-in-italy
#10
Maria Grazia Lazzaretti, Antonio Ponti, Maria Piera Mano, Alessandra Barca, Denise Casella, Alfonso Frigerio, Livia Giordano, Paola Mantellini, Adriana Paduos, Sabina Pitarella, Alessandra Ravaioli, Mario Taffurelli, Mariano Tomatis, Nereo Segnan
OBJECTIVES: Available evidence on axillary surgery has accumulated dramatically in the last two decades in favor of less invasive care. The aim of this paper is to study 16-years trends in the surgical management of the axilla in a large population-based data set of screen-detected breast cancers in Italy and to document at what extent recommendations have been adopted in actual clinical care. MATERIAL AND METHODS: This is a retrospective cohort study documenting the surgical management of the axilla in primary breast cancer patients over time...
August 14, 2018: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/30121548/local-recurrence-outcomes-after-breast-conserving-surgery-and-adjuvant-radiotherapy-in-ductal-carcinoma-in-situ-of-the-breast-and-a-comparison-with-ecog-e5194-study
#11
Ozlem Ozkaya Akagunduz, Arzu Ergen, Petek Erpolat, Melis Gultekin, Berna Akkus Yildirim, Murteza Parvizi, Didem Ikiz, Didem Colpan Oksuz, Cem Onal, Ferah Yildiz, Zeynep Ozsaran
PURPOSE: Turkish Radiation Oncology Study Group investigated local recurrence rates and prognostic factors in patients with ductal carcinoma in situ (DCIS) of the breast treated with breast conservative surgery (BCS) followed by radiotherapy (RT) and Eastern Cooperative Oncology Group (ECOG) Study E5194 were compared with the original study. PATIENTS AND METHODS: Totally 252 patients were evaluated retrospectively. Prognostic factors that might influence local control (age, nuclear grade, comedo necrosis, surgical margins, tumor size, hormone receptor status) were compared...
August 10, 2018: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/30118901/ribociclib-plus-letrozole-and-concomitant-palliative-radiotherapy-for-metastatic-breast-cancer
#12
Icro Meattini, Isacco Desideri, Vieri Scotti, Gabriele Simontacchi, Lorenzo Livi
Ribociclib is a CDK4-6 inhibitor recently approved by the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) as first-line treatment for metastatic breast cancer (MBC). The pivotal trial showed a significant improvement in progression-free survival when compared to endocrine therapy alone. However, having a challenging toxicity profile in comparison with exclusive endocrine therapy, safety may be a concern when combined to radiotherapy (RT) with palliative approach. There are no available published data regarding the combination of ribociclib and palliative RT...
August 9, 2018: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/30149234/characteristics-and-follow-up-of-metastatic-breast-cancer-in-ethiopia-a-cohort-study-of-573-women
#13
Christina Mirjam Weiner, Assefa Mathewos, Adamu Addissie, Wondimu Ayele, Abraha Aynalem, Tigeneh Wondemagegnehu, Andreas Wienke, Ahmedin Jemal, Peter Zerche, Christoph Thomssen, Andreas Seidler, Eva Johanna Kantelhardt
OBJECTIVES: There is little information on characteristics, treatment and outcome of metastatic breast cancer (mBC) patients in low-income countries. This study aims to describe mBC in the setting of Ethiopia. MATERIALS AND METHODS: A retrospective cohort study was conducted among all female mBC patients from the only oncologic hospital in Addis Ababa 01/2006 to 12/2010. Time between first metastasis and known death or loss to follow-up for more than six months as surrogate for death were used for Cox proportional hazards model...
August 7, 2018: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/30193185/variations-in-the-breast-reconstruction-rate-in-france-a-nationwide-study-of-19-466-patients-based-on-the-french-medico-administrative-database
#14
Claudia Régis, Joconde Le, Marie-Pierre Chauvet, Marie-Cécile Le Deley, Gwenael Le Teuff
BACKGROUND: Access to breast reconstruction (BR) surgery after a mastectomy remains limited, with a large degree of national and international variation despite its known psychological benefits and impact on quality of life. The aim of this study was to investigate the factors influencing breast reconstruction in France where cancer-related healthcare costs are fully reimbursed. METHODS: All primary mastectomies for breast carcinoma performed in 2012 and linked BR surgeries from 2012 to December 2015 were extracted from the French medico-administrative database...
August 6, 2018: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/30118902/breast-conserving-therapy-for-primary-ductal-carcinoma-in-situ-in-the-netherlands-a-multi-center-study-and-population-based-analysis
#15
Jan J Jobsen, Luc J E E Scheijmans, Wilma G J M Smit, Marika C Stenfert Kroese, Henk Struikmans, Job van der Palen
OBJECTIVE: The aim of this study was to analyse the efficacy of breast-conserving therapy (BCT) for women with primary DCIS in a population-based setting. METHODS: Data were used from five Radiotherapy centres in The Netherlands from 2000 to 2010, all treated with BCT. Of all the cases, 59.2% received a boost of radiotherapy after their whole breast irradiation (WBI), irrespective of margin status. RESULTS: A total of 1248 cases with primary DCIS were analysed...
July 18, 2018: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/30103105/three-dimensional-primary-cultures-for-selecting-human-breast-cancers-that-are-sensitive-to-the-anti-tumor-activity-of-ipatasertib-or-taselisib-in-combination-with-anti-microtubule-cytotoxic-drugs
#16
M Orditura, C M Della Corte, A Diana, V Ciaramella, E Franzese, V Famiglietti, I Panarese, R Franco, A Grimaldi, A Lombardi, M Caraglia, A Santoriello, E Procaccini, E Lieto, E Maiello, F De Vita, F Ciardiello, F Morgillo
Two inhibitors of phosphatidylinositol 3-kinase (PI3K) pathway taselisib, targeting the mutant PI3K-subunit-alpha (PI3KA) and ipatasertib, AKT-inhibitor, are currently under clinical investigation in breast cancer (BC) patients. We have previously demonstrated the anti-tumor efficacy of these anti-PI3K/AKT-inibitors in combination with anti-microtubule drugs in human BC cell lines, through a complete cytoskeleton disorganization. In this work, we generated ex-vivo three-dimensional (3D) cultures from human BC as a model to test drug efficacy and to identify new molecular biomarkers for selection of BC patients suitable for anti-PI3K/AKT-inibitors treatment...
October 2018: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/30099327/a-cost-utility-analysis-comparing-large-volume-displacement-oncoplastic-surgery-to-mastectomy-with-single-stage-implant-reconstruction-in-the-treatment-of-breast-cancer
#17
Ammar Asban, Christopher Homsy, Lilian Chen, Carla Fisher, Albert Losken, Abhishek Chatterjee
BACKGROUND: For larger cancers in moderate to large breast sized women, breast surgical cancer treatment may include large volume displacement oncoplastic surgery (LVOS) or mastectomy with single stage implant reconstruction (SSIR). Often in the case of LVOS, reduction mammaplasty designs are used in the oncoplastic reconstructions with a contralateral symmetry operation. The goal of this study was to investigate the cost-utility between LVOS versus SSIR to determine which approach is cost-effective in the treatment of breast cancer...
October 2018: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/30099326/impact-of-subtypes-and-comorbidities-on-breast-cancer-relapse-and-survival-in-population-based-studies
#18
Silvia M Ess, Christian Herrmann, Christine Bouchardy, Isabelle Neyroud, Elisabetta Rapiti, Isabelle Konzelmann, Andrea Bordoni, Laura Ortelli, Sabine Rohrmann, Harald Frick, Mohsen Mousavi, Beat Thürlimann
OBJECTIVE: To study the impact of subtypes and comorbidities on breast cancer (BC) relapse and survival in the heterogeneous patients of the real world. METHODS: We identified patients diagnosed with BC between January 2003 and December 2005 from six population-based Swiss cancer registries. Clinicopathologic data was completed with information on locoregional and distant relapse and date and cause of death for over 10-years. We approximated BC subtypes using grade and the immunohistochemical panel for oestrogen, progesterone and human epidermal growth factor 2 (HER2) receptor status...
October 2018: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/30092501/a-novel-patient-decision-aid-for-aftercare-in-breast-cancer-patients-a-promising-tool-to-reduce-costs-by-individualizing-aftercare
#19
Linda A Klaassen, Carmen D Dirksen, Liesbeth J Boersma, Ciska Hoving
OBJECTIVE: A patient decision aid (PtDA), was developed to support breast cancer patients making choices about their aftercare. The aim of this pilot was to test the effects of the PtDA on Shared Decision Making (SDM), Decision Evaluation (DES) in patients, consultation time, choice of aftercare and hospital costs. METHODS: A prospective before-and-after study including a control (no PtDA-usage) and experimental group (PtDA-usage during consultation) was conducted in six hospitals...
October 2018: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/30092500/t-dm1-and-brain-metastases-clinical-outcome-in-her2-positive-metastatic-breast-cancer
#20
Alessandra Fabi, Daniele Alesini, Enrichetta Valle, Luca Moscetti, Roberta Caputo, Michele Caruso, Luisa Carbognin, Mariangela Ciccarese, Nicla La Verde, Grazia Arpino, Katia Cannita, Ida Paris, Daniele Santini, Filippo Montemurro, Michelangelo Russillo, Gianluigi Ferretti, Gianfranco Filippelli, Rosalba Rossello, Agnese Fabbri, Alberto Zambelli, Vita Leonardi, Anna Maria D'Ottavio, Cecilia Nisticò, Simonetta Stani, Marianna Giampaglia, Giusy Scandurra, Giovanna Catania, Paola Malaguti, Diana Giannarelli, Francesco Cognetti
BACKGROUND: We reported the results of an Italian large retrospective analysis that evaluated the effectiveness and safety of T-DM1 in 'field-practice' breast cancer patients. We performed a sub-analysis to investigate the clinical activity of T-DM1 in patients with brain metastases (BMs). METHODS: The records of 87 adult women with HER2-positive breast cancer and BMs treated with T-DM1 were reviewed. Their clinical outcomes were compared with those of 216 patients without central nervous system (CNS) involvement...
October 2018: Breast: Official Journal of the European Society of Mastology
journal
journal
31139
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"